Bnp Paribas Asset Management Holding S.A. Crinetics Pharmaceuticals, Inc. Transaction History
Bnp Paribas Asset Management Holding S.A.
- $41 Billion
- Q2 2025
A detailed history of Bnp Paribas Asset Management Holding S.A. transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Bnp Paribas Asset Management Holding S.A. holds 712,719 shares of CRNX stock, worth $31.6 Million. This represents 0.05% of its overall portfolio holdings.
Number of Shares
712,719
Previous 610,839
16.68%
Holding current value
$31.6 Million
Previous $20.5 Million
0.05%
% of portfolio
0.05%
Previous 0.05%
Shares
12 transactions
Others Institutions Holding CRNX
# of Institutions
238Shares Held
90.2MCall Options Held
59.7KPut Options Held
14.8K-
Vanguard Group Inc Valley Forge, PA9.26MShares$410 Million0.0% of portfolio
-
Driehaus Capital Management LLC Chicago, IL6.4MShares$284 Million1.78% of portfolio
-
Black Rock Inc. New York, NY6.23MShares$276 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA5.81MShares$257 Million0.03% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.59MShares$248 Million0.02% of portfolio
About Crinetics Pharmaceuticals, Inc.
- Ticker CRNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,752,800
- Market Cap $2.38B
- Description
- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...